Regen BioPharma, Inc. Determines Its Lead NR2F6 Agonist Ready for Inflammatory Bowel Disease Animal Studies

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that its lead NR2F6 small molecule agonist,…